The estimated Net Worth of James R Meyers is at least $341 millier dollars as of 16 January 2018. Mr. Meyers owns over 100,000 units of Sangamo Therapeutics Inc stock worth over $86,281 and over the last 18 years he sold SGMO stock worth over $0. In addition, he makes $254,758 as Independent Director at Sangamo Therapeutics Inc.
James has made over 6 trades of the Sangamo Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of SGMO stock worth $2,158,000 on 16 January 2018.
The largest trade he's ever made was exercising 100,000 units of Sangamo Therapeutics Inc stock on 16 January 2018 worth over $2,158,000. On average, James trades about 4,745 units every 105 days since 2007. As of 16 January 2018 he still owns at least 102,715 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Mr. Meyers stock trades at the bottom of the page.
James R. Meyers serves as Independent Director of the Company. He has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Meyers worked at Gilead Sciences, Inc., or Gilead, from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations from November 2016 to February 2018, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. Mr. Meyers joined Gilead in 1996 where he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the board of directors of two public companies, Arbutus Biopharma Corporation and CytomX Therapeutics, Inc., and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College. The Nominating and Corporate Governance Committee and the Board believe that Mr. Meyers’ extensive commercial leadership experience in the biotechnology industry provides valuable operational, commercial assessment and management skills to the Board.
As the Independent Director of Sangamo Therapeutics Inc, the total compensation of James Meyers at Sangamo Therapeutics Inc is $254,758. There are 7 executives at Sangamo Therapeutics Inc getting paid more, with Alexander Macrae having the highest compensation of $3,986,560.
James Meyers is 55, he's been the Independent Director of Sangamo Therapeutics Inc since 2019. There are 9 older and 9 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.
James's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND, CA, 94084.
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp et Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: